Drug intelligence / Profile preview

alemtuzumab + rituximab + mycophenolic acid

Development stage: Preclinical
Lead developer: University of Cambridge
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination immunosuppressive therapy consisting of alemtuzumab (anti-CD52 monoclonal antibody), rituximab (anti-CD20 monoclonal antibody), and mycophenolic acid (IMPDH inhibitor). This regimen causes profound depletion of T and B lymphocytes through multiple mechanisms and has been studied in refractory chronic lymphocytic leukemia and potentially in transplantation settings.

Targets

IMPDH (Inosine-5'-monophosphate dehydrogenase 1)CD20 (B-lymphocyte antigen CD20)CD52 (CD52 Antigen)

Beyond the preview

Go deeper on alemtuzumab + rituximab + mycophenolic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alemtuzumab + rituximab + mycophenolic acid.

Explore the full profile